0001209191-18-038189.txt : 20180615
0001209191-18-038189.hdr.sgml : 20180615
20180615191234
ACCESSION NUMBER: 0001209191-18-038189
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180613
FILED AS OF DATE: 20180615
DATE AS OF CHANGE: 20180615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brege Laura
CENTRAL INDEX KEY: 0001365619
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 18903396
MAIL ADDRESS:
STREET 1: C/O ONYX PHARMACEUTICALS, INC.
STREET 2: 2100 POWELL STREET
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-13
0
0001396814
Pacira Pharmaceuticals, Inc.
PCRX
0001365619
Brege Laura
C/O PACIRA PHARMACEUTICALS, INC.
5 SYLVAN WAY, SUITE 300
PARSIPPANY
NJ
07054
1
0
0
0
Common Stock
2018-06-13
4
A
0
782
0.00
A
4627
D
Stock Option (Right to Buy)
38.35
2018-06-13
4
A
0
4693
0.00
A
2028-06-13
Common Stock
4693
4693
D
Represents restricted stock units that vest on June 3, 2019, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date.
/s/ Kristen Williams, Attorney-in-Fact
2018-06-15